Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2002-10-10
2008-11-18
Helms, Larry R. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C536S023530, C424S093200
Reexamination Certificate
active
07452976
ABSTRACT:
There are disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human KDR. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases in which VEGF and/or KDR are implicated.
REFERENCES:
patent: 6133426 (2000-10-01), Gonzalez et al.
patent: 0 239 400 (1987-09-01), None
patent: 1 086 705 (2001-03-01), None
patent: WO 89/01476 (1989-02-01), None
patent: WO 90/07861 (1990-07-01), None
patent: WO 90/09195 (1990-08-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO 92/01059 (1992-01-01), None
patent: WO 92/22583 (1992-12-01), None
patent: WO 93/06231 (1993-04-01), None
patent: WO 94/11499 (1994-05-01), None
patent: WO 98/11223 (1998-03-01), None
patent: WO 98/20734 (1998-05-01), None
patent: WO 98/58053 (1998-12-01), None
patent: WO 99/64460 (1999-12-01), None
patent: WO 00/44777 (2000-08-01), None
Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295.
Rudikoff et al. Proc. Natl. Acad. Sci. USA, 79:1979-1983, Mar. 1982.
Colman. Research in Immunology, 145:33-36, 1994.
Bendig M. M. Methods: A Companion to Methods in Enzymology, 1995; 8:83-93.
MacCallum et al. J. Mol. Biol., 262, 732-745, 1996.
Casset et al. Biochemical and Biophysical Research Communications, 307:198-205, 2003.
William E. Paul, M.D. Fundamental Immunology ed., 3d ed. 1993, p. 242.
Ausubel (Ed.), Current Protocols in Molecular Biology, Wiley, NY (1999).
Brekken, R.A., et al., “Selective Inhibition of Vascular Endothelial Growth Factor (VEGF) Receptor 2 (DKR/Flk-1) Activity by a Monoclonal Anti-VEGF Antibody Blocks Tumor Growth in Mice,”Cancer Research, 60:5117-5124, (Sep. 2000).
Brown, L.F., et al., “Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) and Its Receptors in Adenocarcinomas of the Gastrointestinal Tract,”Cancer Research, 53:4727-4735, (Oct. 1993).
Brown, L.F., et al., “Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) and its Receptors in Breast Cancer,”Human Pathol., 26:86-91, (1995).
Chapman, A.P., “Therapeutic antibody fragments with prolonged in vivo half-lives,”Nature Biotechnology, 17:780-783, (Aug. 1999).
Cheng, S.Y., et al., “Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor,”Proc. Natl. Acad. Sci., USA, 93:8502-8507, (Aug. 1996).
Crameri, A., et al., “DNA shuffling of a family of genes from diverse species accelerates directed evolution,”Nature, 391(6664):288-291, (Jan. 1988).
Cunningham, S.A., et al., “KDR activation is crucial for VEGF165-mediated Ca2+ mobilization in human umbilical vein endothelial cells,”Am. J. Physiol., 276(Cell Physiol., 45):C176-C181, (1999).
Deckert, P.M., et al., “Pharmacokinetics and Microdistribution of Polyethylene Glycol-Modified Humanized A33 Antibody Targeting Colon Cancer Xenografts,”Int. J. Cancer, 87(3):382-390, (2000).
Dvorak, H.F., et al., “Vascular Permeability Factor/Vascular Endothelial Growth Factor and the Significance of Microvascular Hyperpermeability in Angiogeneis,”Curr. Topics Microbiol. Immunol., 237:97-132, (1999).
Flanagan, J.G. and Rabbitts, T.H., “Arrangement of human immunoglobulin heavy chain constant region genes implies evolutionary duplication of a segment containing γ, ε and α genes,”Nature, 300(5894):709-713, (Dec. 1982).
Folkman, J. and Klagsbrun, M., “Angiogenic Factors,”Science, 235:442-447, (Jan. 1987).
Gerber, H.P., et al., “Vascular Endothelial Growth Factor Regulates Endothelial Cell Survival through the Phosphatidylinositol 3′-Kinase/Akt Signal Transduction Pathway,”J. Biol. Chem., 273(46):30336-30343, (Nov. 1998).
Goldman, C.K., et al., “Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate,”Proc. Natl. Acad. Sci., USA, 95:8795-8800, (Jul. 1998).
Hicklin, D.J., et al., “Monoclonal antibody strategies to block angiogenesis,”Drug Discovery Today, 6(10):517-528, (2001).
Hieter, P.A., et al., “Cloned Human and Mouse Kappa Immunoglobulin Constant and J Region Genes Conserve Homology in Functional Segments,”Cell, 22(Part 1):197-207, (Nov. 1980).
Hiratsuka, S., et al., “FLT-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice,”Proc. Natl. Acad. Sci., USA, 95:9349-9354, (Aug. 1998).
Hurwitz, E., et al., “Inhibition of tumor growth by poly(ethylene glycol) derivatives of anti-ErbB2 antibodies,”Cancer Immunol. Immunother., 49(4-5):226-234, (2000).
Kabat, et al., “In Sequences of Proteins of Immunological Interest,” U.S. Department of Health and Human Services, NIH, USA, (1987).
Keyt, B.A., et al., “Identification of Vascular Endothelial Growth Factor Determinants for Binding KDR and FLT-1 Receptors,”J. Biol. Chem., 271(10):5638-5646, (Mar. 1996).
Kim, K.J., et al., “Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo,”Nature, 362:841-844, (Apr. 1993).
Koukourakis, M.I., et al., “Vascular Endothelial Growth Factor/KDR Activated Microvessel Density versus CD31 Standard Microvessel Density in Non-Small Cell Lung Cancer,”Cancer Research, 60:3088-3095, (Jun. 2000).
Larrivee, B. and Karsan, A., “Signaling pathways induced by vascular endothelial growth factor (Review),”Intl. J. Molecular Medicine, 5:447-456, (2000).
Low, N.M., et al., “Mimicking Somatic Hypermutation: Affinity Maturation of Antibodies Displayed on Bacteriophage Using a Bacterial Mutator Strain,”J. Mol. Biol., 260:359-368, (1996).
Marks, J.D., “By-Passing Immunization: Building High Affinity Human Antibodies By Chain Shuffling,”Bio/Technology, 10:779-783, (Jul. 1992).
Millauer, B., et. al., “Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant,”Nature, 367:576-579, (Feb. 1994).
Patten, P.A., et al., “Applications of DNA shuffling to pharmaceuticals and vaccines,”Current Opinion in Biotechnology, 87:724-733, (1997).
Riechmann, L., et al., “Reshaping human antibodies for therapy,”Nature, 332:323-327, (Mar. 1988).
Shibuya, M., et al., “Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family,”Oncogene, 5:519-524, (1990).
Takahashi, Y., et al., “Expression of Vascular Endothelial Growth Factor and Its Receptor, KDR, Correlates with Vascularity, Metastasis, and Proliferation of Human Colon Cancer,”Cancer Research, 55:3964-3968, (Sep. 1995).
Terman, B.I., et al., “Identification of a new endothelial cell growth factor receptor tyrosine kinase,”Oncogene, 6:1677-1683, (1991).
Thompson, J., et al., “Affinity Maturation of a High-affinity Human Monoclonal Antibody Against the Third Hypervariable Loop of Human Immunodeficiency Virus: Use of Phage Display to Improve Affinity and Broaden Strain Reactivity,”J. Mol. Biol., 256:77-88, (1996).
Vaughan, T., et al., “Human antibodies by design,”Nature Biotechnology, 16:535-539, (Jun. 1998).
Wada K.N., et al., “Codon usage tabulated from the GenBank genetic sequence data,”Nucleic Acids Research, 19(Supplement):1981-1986, (1991).
Waltenberger, J., et al., “Different Signal Transduction Properties of KDR and Flt1, Two Receptors for Vascular Endothelial Growth Factor,”J. Biol. Chem., 269(43):26988-26995, (Oct. 1994).
Witte, L., et al., “Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy,
Morrison Robert Kendall
Popplewell Andrew George
Tickle Simon Peter
Zinkewich-Peotti Karen
Helms Larry R.
Natarajan Meera
O'Connor Cozen
UCB Pharma S.A.
LandOfFree
Biological products does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biological products, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biological products will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4028762